iwNHL 2017 | T-cell lymphoma: autologous or allogeneic transplant?
Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses the role of transplantation in T-cell lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada. The current NCCN guidelines recommend autologous transplantation for patients with aggressive T-cell lymphoma, however, it is not clearly defined which patients will benefit from this treatment. Approximately 60% of patients who receive an autologous transplant progress within 5 years. It needs to be determined if there is a role for maintenance therapy after autologous transplant, to improve this response rate. The role of allogeneic transplant must also be further explored as a potentially curative modality. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.
Get great new content delivered to your inboxSign up